Skip to content
You are now leaving to visit

Advances in Ionis’ Novel Antisense Technology to be Presented at 2018 Society for Neuroscience Meeting

12 presentations highlighting latest data from Ionis’ Neurodegenerative Program including first-in-class therapies for untreatable diseases such as Alzheimer’s, ALS, Alexander, and spinocerebellar ataxia type 3 CARLSBAD, Calif. , Oct. 31, 2018 /PRNewswire/ —  Ionis Pharmaceuticals, Inc.